Glychek 80 Tablet contains Gliclazide 80mg, an oral hypoglycemic agent belonging to the sulfonylurea class, primarily indicated for the management of type 2 diabetes mellitus. Gliclazide functions by stimulating pancreatic beta cells to release insulin, thereby improving glycemic control in patients with non-insulin-dependent diabetes. It is particularly effective in patients whose hyperglycemia cannot be adequately controlled by diet and exercise alone. Glychek 80 Tablet helps reduce both fasting and postprandial blood glucose levels, contributing to the prevention of long-term diabetic complications such as neuropathy, nephropathy, and retinopathy. The medication should be administered orally, usually once daily with breakfast, and dosage adjustments must be individualized based on patient response and glycemic targets. Caution is advised in patients with hepatic or renal impairment, and it is contraindicated in individuals with type 1 diabetes, diabetic ketoacidosis, or hypersensitivity to sulfonylureas. Common adverse effects include hypoglycemia, gastrointestinal disturbances, and allergic skin reactions. Regular monitoring of blood glucose and periodic assessment of renal and hepatic function are recommended during therapy. Glychek 80 Tablet should be used as part of a comprehensive diabetes management plan including diet, exercise, and lifestyle modifications.